Dare Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 11, 2026, specifically the results of the company's 2026 Annual Meeting of Stockholders. Dare Bioscience, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol DARE.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are reported in this document.
Material Changes and Corporate Actions
The primary material event reported is the successful approval of several proposals by stockholders at the Annual Meeting:
- Equity Plan Amendment: Stockholders approved an amendment to the 2022 Stock Incentive Plan to increase the number of shares available for issuance by 1,500,000.
- Director Elections: Gregory W. Matz, CPA, and Sabrina Martucci Johnson were elected as Class III directors to serve until the 2029 annual meeting.
- Equity Line Approval: Stockholders approved the potential future issuance of shares under the company's existing equity line with Lincoln Park Capital Fund, LLC.
- Accounting Firm Ratification: Haskell & White LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. The document focuses exclusively on the voting results of the Annual Meeting. Notably, the board determined to hold an advisory vote on executive compensation every year based on the voting results for Proposal 4.
Investor Verification Checklist
- Verify the impact of the 1,500,000 share increase to the 2022 Stock Incentive Plan on potential future dilution.
- Review the terms of the equity line with Lincoln Park Capital Fund, LLC to understand potential share issuance mechanics.
- Confirm the tenure of the newly elected directors (Gregory W. Matz and Sabrina Martucci Johnson) through 2029.
- Check subsequent filings for the actual utilization of the approved equity line and stock plan shares.